PROSTIN E2 Drug Patent Profile

Which patents cover Prostin E2, and when can generic versions of Prostin E2 launch?

Prostin E2 is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in PROSTIN E2 is dinoprostone. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dinoprostone profile page.

Summary for PROSTIN E2

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	72
Clinical Trials:	12
Patent Applications:	3,242
Drug Prices:	Drug price information for PROSTIN E2
DailyMed Link:	PROSTIN E2 at DailyMed

See drug prices for PROSTIN E2

Recent Clinical Trials for PROSTIN E2

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Medical Centre Maribor	Phase 4
Aswan University Hospital	N/A
National University, Singapore	N/A

See all PROSTIN E2 clinical trials

US Patents and Regulatory Information for PROSTIN E2

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	PROSTIN E2	dinoprostone	SUPPOSITORY;VAGINAL	017810-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for PROSTIN E2

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	PROSTIN E2	dinoprostone	SUPPOSITORY;VAGINAL	017810-001	Approved Prior to Jan 1, 1982	3,598,858
Pfizer	PROSTIN E2	dinoprostone	SUPPOSITORY;VAGINAL	017810-001	Approved Prior to Jan 1, 1982	3,899,587

International Patents for PROSTIN E2

See the table below for patents covering PROSTIN E2 around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	1160981	Verfahren zur Gewinnung von kristallisiertem PGE und PGF
Germany	1443474
Germany	1643738	7-[3alpha,5alpha-Dihydroxy-2-(3-hydroxyoctenyl-(1))-cyclopentyl]-heptan-1-ol,dessen Tetraacetat und Verfahren zu deren Herstellung
Germany	1643739	Epi-PGF,Bisdehydro-epi-PGF,Tetradehydro-epi-PGF,deren Methylester und Methylestertriacetate und Verfahren zu ihrer Herstellung

Last updated: April 25, 2026

PROSTIN E2: Market dynamics and financial trajectory

Prostin E2 (dinoprostone, PGE2) is a mature, genericized product line with limited scope for incremental market expansion. Market dynamics are dominated by guideline-driven use, hospital procurement economics, and ongoing supply reliability rather than patent-protected innovation. Financial trajectory reflects (1) long-standing generic competition, (2) use-case concentration in specific therapeutic settings, and (3) payer-driven pricing pressure in tender-based procurement markets.

What is Prostin E2’s market structure and demand anchor?

Product identity and positioning

• Active ingredient: dinoprostone (prostaglandin E2, PGE2)
• Brand name in scope: Prostin E2 (marketed as dinoprostone for approved indications; formulation and route are specific to the marketed product in each jurisdiction)
• Therapeutic class: prostaglandins; hormone-like lipid mediators used where clinical protocols require PGE2 activity.

Demand drivers Demand is anchored to settings where prostaglandin E2 is embedded in standard-of-care pathways, including:

• obstetric induction and cervical ripening protocols where PGE2 products are used as options in defined clinical circumstances
• institutional use in labor and delivery units, where usage is concentrated by hospital formularies and protocol governance

Where demand sits financially For mature prostaglandin products, revenue is typically driven by:

• volume churn in hospital formularies and procurement cycles
• price erosion from generic entries
• substitution across prostaglandin formats (same class) and across route options when protocols allow

How do competitive dynamics shape pricing and share?

Generic and tender economics

• Prostin E2 operates in a market structure where generic competition suppresses brand pricing and forces manufacturers to compete on procurement terms.
• Hospital buying is typically tender-led and formulary-rebate influenced, which makes net pricing more sensitive to contracting and distribution than to wholesale list price.

Competition vectors 1) Direct generics of dinoprostone (PGE2)

• Compete on unit price, availability, and contracting terms. 2) Therapeutic class alternatives
• Clinicians and procurement teams consider prostaglandin alternatives and non-prostaglandin induction options depending on institution protocols and patient eligibility. 3) Supply reliability
• In hospital-centric markets, procurement continuity can outweigh marginal clinical differences.

Implication for market share In mature segments, share shifts often reflect:

• stocking agreements
• product availability and lead times
• substitution behavior under protocol changes
• distributor coverage and contract duration

What are the principal market risks for Prostin E2?

1) Protocol shift risk Clinical pathway evolution can move utilization to alternative molecules or administration formats. Even when PGE2 remains clinically accepted, utilization rates can contract when protocols tighten eligibility.

2) Supply chain and manufacturing risk Prostaglandin products are sensitive to manufacturing consistency and distribution continuity. Any disruption can cause short-term stockouts with downstream purchasing behavior changes that persist into subsequent procurement cycles.

3) Pricing pressure and margin compression With generic competition, manufacturers experience:

• lower gross margins
• increased reliance on scale and contract penetration
• higher effective marketing and account management costs to defend tender awards

How does the financial trajectory typically evolve for a mature PGE2 product?

Trajectory pattern For non-exclusivity and generic pressure products, financial trajectory usually follows a “volume vs price” tradeoff:

• Unit volumes can remain stable if the product stays in standard protocols
• Revenue trends down as average net price erodes
• Upside occurs only when a firm gains share through contracts or mitigates competitive price pressure through supply and service

Observed drivers of revenue stability Prostin E2 can maintain revenue resilience when:

• it retains formulary positioning across large hospital networks
• supply reliability remains high and lead times stay consistent
• substitution pressure is limited by protocol constraints or clinician familiarity

Observed drivers of revenue decline Revenue typically falls when:

• additional generics or competing prostaglandin formats enter procurement
• tender auctions reprice the category downward
• formulary exclusion or protocol adjustments reduce patient eligible populations

What is the likely regional market dynamic?

Hospital procurement markets Prostaglandin products are most revenue-relevant in hospital procurement channels:

• concentrated by region’s obstetric service density
• shaped by reimbursement structures that govern tender thresholds and budget impact

Pricing heterogeneity Net pricing differs materially across markets because:

• tender mechanisms differ (single-award vs multi-award)
• reimbursement levels and contracting norms vary
• local generic density changes the price floor

What does the commercial outlook imply for investors or R&D planners?

Revenue expectations

• Near-term revenue is more dependent on procurement execution than on innovation.
• Growth is more likely through share gains (contract awards) than through category expansion.

R&D and portfolio positioning

• Incremental R&D is generally harder to justify unless there is a defensible differentiation in formulation, delivery system, stability, or regulatory pathway.
• For firms without manufacturing scale or distribution reach, the competitive bar is high because winning tenders requires reliable supply and competitive net pricing.

Financial discipline signals

• Expect margin variability tied to manufacturing cost controls and contract mix.
• Cash flow stability depends on working capital and inventory planning aligned to tender cycles.

---

Key Takeaways

• Prostin E2 (dinoprostone, PGE2) is a mature, hospital-driven product line where demand follows guideline-linked obstetric protocols.
• Market dynamics are dominated by generic competition, tender contracting, and supply reliability, which collectively pressure pricing and margins.
• The financial trajectory typically declines in average net price over time, with revenue stability possible only via formulary retention and share gains from procurement awards.
• Investment and R&D upside is constrained unless a company can secure durable contract share or deliver a meaningful, regulator-grade differentiation that alters substitution behavior.

---

FAQs

1) Is Prostin E2 growth driven by new clinical adoption or contracting?

Contracting and procurement execution drive outcomes. Category utilization is protocol-bound, while financial results move with tender pricing, hospital formulary status, and supply consistency.

2) What most directly impacts Prostin E2 net revenue?

Average net price after tender discounts and rebates, tempered by the ability to retain formulary inclusion and win contracts that maintain volume.

3) Does generic competition eliminate the product’s commercial value?

It compresses brand economics and margins but does not remove commercial value if the product remains protocol-anchored and reliably stocked in hospital systems.

4) What operational factors most affect financial performance?

Manufacturing yield, supply continuity, distributor coverage, and inventory discipline aligned to procurement cycles.

5) Where is the highest risk to revenue?

Formulary exclusion and protocol shifts that reduce the eligible patient population, combined with competitive re-tendering that drives lower category pricing.

---

References

[1] U.S. Food and Drug Administration (FDA). Prostin E2 (dinoprostone) prescribing information. FDA Drugs@FDA.
[2] FDA. Drugs@FDA database record for dinoprostone (Prostin E2). FDA.
[3] Clinical obstetrics guidelines and standard labor management references that include dinoprostone as an option for induction/cervical ripening (institutional protocol literature).